NeuralStem
NeuralStem is a publicly traded, clinical-stage biotherapeutics company that develops neural stem cell-based therapies for central nervous system diseases. Founded in 1996 in Rockville, Maryland, it operates with 11-50 employees under founder-CEO I. Richard Garr.
- Company typePrivate
- Founded1996
- HeadquartersRockville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeuralStem does
NeuralStem is a publicly traded clinical-stage biotherapeutics company (NASDAQ: SNCA) founded in 1996 and headquartered in Rockville, Maryland. The company is focused on applying neural stem cell research and technology to develop treatments for diseases of the central nervous system (CNS). It operates with a small team of 11-50 employees under founder, president and CEO I. Richard Garr.
NeuralStem's core technology platform centers on proprietary human neural stem cell lines and the methods to differentiate, manufacture, and deliver these cells as potential therapies for CNS indications. The company has historically pursued cell-based therapeutic candidates targeting conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injury, and ischemic stroke, among other CNS disorders. Specific product candidates, IND status, and clinical pipeline details are not disclosed in the available input, but the platform implies a long, capital-intensive R&D cycle typical of cell therapy developers.
The business model is that of a pre-revenue clinical-stage biotech: NeuralStem funds its R&D through periodic equity and structured financings rather than product sales. Cumulative disclosed funding totals approximately $39.86M across seven rounds between 2010 and 2019, the largest being a $20M strategic investment from Tianjin Pharmaceutical Group International Holdings in December 2016. There is no disclosed product revenue, pricing, customer base, or partnership royalty stream; revenue mechanics will depend on future commercialization, licensing, or partnership milestones rather than current operating activity.
NeuralStem firmographics
Firmographics- Name
- NeuralStem
- Website
- https://neuralstem.com
- Company type
- Private
- Founded year
- 1996
- Headcount range
- 11–50 employees
- Short description
- NeuralStem is a publicly traded, clinical-stage biotherapeutics company that develops neural stem cell-based therapies for central nervous system diseases. Founded in 1996 in Rockville, Maryland, it operates with 11-50 employees under founder-CEO I. Richard Garr.
- Ownership category
- akta.pro rank
NeuralStem industry classification
Industry- Product category
- Stem Cell Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neural & Spinal Cord Regeneration (HLAAAGAI)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where NeuralStem is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Markets served
NeuralStem business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
NeuralStem product offering
Product offeringCore offering
NeuralStem is a biotherapeutics company that applies stem cell research and proprietary neural stem cell technology to develop treatments for diseases of the central nervous system. Its core activity is the advancement of cell-based therapeutics targeting conditions such as neurodegenerative disorders and central nervous system injuries.
Differentiator
Problem solved
Functional benefit
Companies that use NeuralStem
Customer profileIdeal customer profiles1 record
NeuralStem technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
NeuralStem partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights2 records
NeuralStem competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights5 records
Customer concentration
NeuralStem social profiles
Digital presenceNeuralStem financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuralStem leadership team
Management profileNumber of profiles
Profiles1 record
NeuralStem funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuralStem M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuralStem
What does NeuralStem do?
NeuralStem is a biotherapeutics company that applies stem cell research and proprietary neural stem cell technology to develop treatments for diseases of the central nervous system. Its core activity is the advancement of cell-based therapeutics targeting conditions such as neurodegenerative disorders and central nervous system injuries.
When was NeuralStem founded?
NeuralStem was founded in 1996. It employs 11 to 50 people.
Where is NeuralStem based?
NeuralStem is headquartered in Rockville, United States, in the North America region.
Does NeuralStem have an API?
No public API is recorded for NeuralStem.
What industry is NeuralStem in?
NeuralStem's product category is Stem Cell Therapeutics. Its primary akta.pro industry code is HLAAAGAI, Neural & Spinal Cord Regeneration, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.